Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
Identifieur interne : 000D75 ( PubMed/Corpus ); précédent : 000D74; suivant : 000D76Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
Auteurs : Jean B. Nachega ; Olalekan A. Uthman ; Lynne M. Mofenson ; Jean R. Anderson ; Steve Kanters ; Francoise Renaud ; Nathan Ford ; Shaffiq Essajee ; Meg C. Doherty ; Edward J. MillsSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
English descriptors
- KwdEn :
- Anti-HIV Agents (therapeutic use), Birth Weight (drug effects), CD4 Lymphocyte Count, Female, HIV Infections (drug therapy), HIV Infections (transmission), Humans, Infant, Low Birth Weight, Infant, Newborn, Infectious Disease Transmission, Vertical (prevention & control), Patient Safety, Pregnancy, Pregnancy Complications, Infectious (drug therapy), Pregnancy Outcome, Tenofovir (adverse effects), Tenofovir (therapeutic use).
- MESH :
- chemical , adverse effects : Tenofovir.
- chemical , therapeutic use : Anti-HIV Agents, Tenofovir.
- drug effects : Birth Weight.
- drug therapy : HIV Infections, Pregnancy Complications, Infectious.
- prevention & control : Infectious Disease Transmission, Vertical.
- transmission : HIV Infections.
- CD4 Lymphocyte Count, Female, Humans, Infant, Low Birth Weight, Infant, Newborn, Patient Safety, Pregnancy, Pregnancy Outcome.
Abstract
There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants.
DOI: 10.1097/QAI.0000000000001359
PubMed: 28291053
Links to Exploration step
pubmed:28291053Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.</title><author><name sortKey="Nachega, Jean B" sort="Nachega, Jean B" uniqKey="Nachega J" first="Jean B" last="Nachega">Jean B. Nachega</name><affiliation><nlm:affiliation>*Departments of Epidemiology, Microbiology and Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; †Department of Medicine, Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa; ‡Departments of Epidemiology and International Health, Johns Hopkins University, Baltimore, MD; §Centre for Applied Health Research & Delivery, Warwick Medical School, The University of Warwick, Coventry, United Kingdom; ‖Department of Public Health (IHCAR), Karolinska Institute, Stockholm, Sweden; ¶Department of Global Health, Centre for Evidence-Based Health Care, Stellenbosch University, Tygerberg, South Africa; #Elizabeth Glazer Pediatric AIDS Foundation, Washington, DC; **Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD; ††Department of Statistics, University of British Columbia, Vancouver, Canada; ‡‡Global Evaluative Science, Vancouver, Canada; and §§Department of HIV, World Health Organization, Geneva, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Uthman, Olalekan A" sort="Uthman, Olalekan A" uniqKey="Uthman O" first="Olalekan A" last="Uthman">Olalekan A. Uthman</name></author><author><name sortKey="Mofenson, Lynne M" sort="Mofenson, Lynne M" uniqKey="Mofenson L" first="Lynne M" last="Mofenson">Lynne M. Mofenson</name></author><author><name sortKey="Anderson, Jean R" sort="Anderson, Jean R" uniqKey="Anderson J" first="Jean R" last="Anderson">Jean R. Anderson</name></author><author><name sortKey="Kanters, Steve" sort="Kanters, Steve" uniqKey="Kanters S" first="Steve" last="Kanters">Steve Kanters</name></author><author><name sortKey="Renaud, Francoise" sort="Renaud, Francoise" uniqKey="Renaud F" first="Francoise" last="Renaud">Francoise Renaud</name></author><author><name sortKey="Ford, Nathan" sort="Ford, Nathan" uniqKey="Ford N" first="Nathan" last="Ford">Nathan Ford</name></author><author><name sortKey="Essajee, Shaffiq" sort="Essajee, Shaffiq" uniqKey="Essajee S" first="Shaffiq" last="Essajee">Shaffiq Essajee</name></author><author><name sortKey="Doherty, Meg C" sort="Doherty, Meg C" uniqKey="Doherty M" first="Meg C" last="Doherty">Meg C. Doherty</name></author><author><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28291053</idno><idno type="pmid">28291053</idno><idno type="doi">10.1097/QAI.0000000000001359</idno><idno type="wicri:Area/PubMed/Corpus">000D75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.</title><author><name sortKey="Nachega, Jean B" sort="Nachega, Jean B" uniqKey="Nachega J" first="Jean B" last="Nachega">Jean B. Nachega</name><affiliation><nlm:affiliation>*Departments of Epidemiology, Microbiology and Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; †Department of Medicine, Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa; ‡Departments of Epidemiology and International Health, Johns Hopkins University, Baltimore, MD; §Centre for Applied Health Research & Delivery, Warwick Medical School, The University of Warwick, Coventry, United Kingdom; ‖Department of Public Health (IHCAR), Karolinska Institute, Stockholm, Sweden; ¶Department of Global Health, Centre for Evidence-Based Health Care, Stellenbosch University, Tygerberg, South Africa; #Elizabeth Glazer Pediatric AIDS Foundation, Washington, DC; **Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD; ††Department of Statistics, University of British Columbia, Vancouver, Canada; ‡‡Global Evaluative Science, Vancouver, Canada; and §§Department of HIV, World Health Organization, Geneva, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Uthman, Olalekan A" sort="Uthman, Olalekan A" uniqKey="Uthman O" first="Olalekan A" last="Uthman">Olalekan A. Uthman</name></author><author><name sortKey="Mofenson, Lynne M" sort="Mofenson, Lynne M" uniqKey="Mofenson L" first="Lynne M" last="Mofenson">Lynne M. Mofenson</name></author><author><name sortKey="Anderson, Jean R" sort="Anderson, Jean R" uniqKey="Anderson J" first="Jean R" last="Anderson">Jean R. Anderson</name></author><author><name sortKey="Kanters, Steve" sort="Kanters, Steve" uniqKey="Kanters S" first="Steve" last="Kanters">Steve Kanters</name></author><author><name sortKey="Renaud, Francoise" sort="Renaud, Francoise" uniqKey="Renaud F" first="Francoise" last="Renaud">Francoise Renaud</name></author><author><name sortKey="Ford, Nathan" sort="Ford, Nathan" uniqKey="Ford N" first="Nathan" last="Ford">Nathan Ford</name></author><author><name sortKey="Essajee, Shaffiq" sort="Essajee, Shaffiq" uniqKey="Essajee S" first="Shaffiq" last="Essajee">Shaffiq Essajee</name></author><author><name sortKey="Doherty, Meg C" sort="Doherty, Meg C" uniqKey="Doherty M" first="Meg C" last="Doherty">Meg C. Doherty</name></author><author><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (therapeutic use)</term><term>Birth Weight (drug effects)</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (transmission)</term><term>Humans</term><term>Infant, Low Birth Weight</term><term>Infant, Newborn</term><term>Infectious Disease Transmission, Vertical (prevention & control)</term><term>Patient Safety</term><term>Pregnancy</term><term>Pregnancy Complications, Infectious (drug therapy)</term><term>Pregnancy Outcome</term><term>Tenofovir (adverse effects)</term><term>Tenofovir (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Tenofovir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Birth Weight</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Infectious Disease Transmission, Vertical</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>CD4 Lymphocyte Count</term><term>Female</term><term>Humans</term><term>Infant, Low Birth Weight</term><term>Infant, Newborn</term><term>Patient Safety</term><term>Pregnancy</term><term>Pregnancy Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28291053</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>14</Day></DateCreated><DateCompleted><Year>2017</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000001359</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review of studies published between January 1980 and January 2017 that compared adverse outcomes in HIV-infected women receiving TDF- vs. non-TDF-based ART during pregnancy. The risk ratio (RR) for associations was pooled using a fixed-effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventeen studies met the study inclusion criteria. We found that the rate of preterm (<37 weeks gestation) delivery (RR = 0.90, 95% confidence interval [CI]: 0.81 to 0.99, I = 59%) and stillbirth (RR = 0.60, 95% CI: 0.43 to 0.84, I = 72.0%) were significantly lower in women exposed (vs. not) to TDF-based ART regimen. We found no increased risk in maternal severe (grade 3) or potentially life-threatening (grade 4) adverse events (RR = 0.62; 95% CI: 0.30 to 1.29), miscarriage (RR = 1.09; 95% CI: 0.80 to 1.48), very preterm (<34 weeks gestation) delivery (RR = 1.08, 95% CI: 0.72 to 1.62), small for gestational age (RR = 0.87, 95% CI: 0.67 to 1.13), low birth weight (RR = 0.91; 95% CI: 0.80 to 1.04), very low birth weight (RR = 3.18; 95% CI: 0.65 to 15.63), congenital anomalies (RR = 1.03; 95% CI: 0.83 to 1.28), infant adverse outcomes or infant mortality (age >14 days) (RR = 0.65; 95% CI: 0.23 to 1.85), but increased neonatal mortality (age <14 days) risk (RR = 5.64, 95% CI: 1.70 to 18.79) with TDR-based ART exposure. No differences were found for anthropomorphic parameters at birth; one study reported minor differences in z-scores for length and head circumference at age 1 year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TDF-based ART in pregnancy seems generally safe for women and their infants. However, data remain limited and further studies are needed, particularly to assess neonatal mortality and infant growth/bone effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nachega</LastName><ForeName>Jean B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>*Departments of Epidemiology, Microbiology and Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; †Department of Medicine, Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa; ‡Departments of Epidemiology and International Health, Johns Hopkins University, Baltimore, MD; §Centre for Applied Health Research & Delivery, Warwick Medical School, The University of Warwick, Coventry, United Kingdom; ‖Department of Public Health (IHCAR), Karolinska Institute, Stockholm, Sweden; ¶Department of Global Health, Centre for Evidence-Based Health Care, Stellenbosch University, Tygerberg, South Africa; #Elizabeth Glazer Pediatric AIDS Foundation, Washington, DC; **Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD; ††Department of Statistics, University of British Columbia, Vancouver, Canada; ‡‡Global Evaluative Science, Vancouver, Canada; and §§Department of HIV, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uthman</LastName><ForeName>Olalekan A</ForeName><Initials>OA</Initials></Author><Author ValidYN="Y"><LastName>Mofenson</LastName><ForeName>Lynne M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Jean R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Kanters</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Renaud</LastName><ForeName>Francoise</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Essajee</LastName><ForeName>Shaffiq</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Doherty</LastName><ForeName>Meg C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D43 TW010340</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U2G GH001536</GrantID><Acronym>GH</Acronym><Agency>CGH CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI069521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2011;16(8):1259-66</RefSource><PMID Version="1">22155907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pediatr. 2008 Apr;152(4):582-4</RefSource><PMID Version="1">18346519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2004 May 15;23(9):1351-75</RefSource><PMID Version="1">15116347</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Mar 13;27(5):739-48</RefSource><PMID Version="1">23169329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2008 Apr 26;336(7650):924-6</RefSource><PMID Version="1">18436948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2010 Aug;29(8):721-7</RefSource><PMID Version="1">20539252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2008 Feb;83(2):265-72</RefSource><PMID Version="1">17597712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):423-34</RefSource><PMID Version="1">22784038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Clin Trials. 2014 Nov-Dec;15(6):231-45</RefSource><PMID Version="1">25433663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2012 Feb;56(2):857-62</RefSource><PMID Version="1">22123690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Nov 3;375(18):1726-1737</RefSource><PMID Version="1">27806243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2010 Sep 1;51(5):496-505</RefSource><PMID Version="1">20673002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2006 Oct 3;20(15):1931-9</RefSource><PMID Version="1">16988514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Pregnancy Childbirth. 2016 Feb 11;16:35</RefSource><PMID Version="1">26867536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):367-374</RefSource><PMID Version="1">27875363</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):428-36</RefSource><PMID Version="1">26379069</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):374-81</RefSource><PMID Version="1">24169122</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19565</RefSource><PMID Version="1">25394072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Pediatr. 2015 Jan;169(1):48-55</RefSource><PMID Version="1">25383770</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2013 Dec;57(12):1773-81</RefSource><PMID Version="1">24046310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2015;20(1):57-64</RefSource><PMID Version="1">24992294</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Aug 15;204(4):506-14</RefSource><PMID Version="1">21791651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2011 May;8(5):e1001026</RefSource><PMID Version="1">21559325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2003 Sep 6;327(7414):557-60</RefSource><PMID Version="1">12958120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2014 Apr 29;11(4):e1001635</RefSource><PMID Version="1">24781315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2012 Feb;31(2):164-70</RefSource><PMID Version="1">21983213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2015 Jan 27;313(4):419</RefSource><PMID Version="1">25626041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Rev. 2013 Jan-Mar;15(1):38-48</RefSource><PMID Version="1">23449228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2016 Nov;71(11):3206-3211</RefSource><PMID Version="1">27494909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):207-20</RefSource><PMID Version="1">11873070</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2010 Oct 15;51(8):963-72</RefSource><PMID Version="1">20828304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2011 Jun;55(6):2961-7</RefSource><PMID Version="1">21464249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 17;362(24):2282-94</RefSource><PMID Version="1">20554983</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22</RefSource><PMID Version="1">21896911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2012;9(5):e1001217</RefSource><PMID Version="1">22615543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Jun 1;26(9):1151-9</RefSource><PMID Version="1">22382151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):278-83</RefSource><PMID Version="1">17079992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Jun 15;203(12):1791-801</RefSource><PMID Version="1">21606537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Nutr. 2016 Aug;70(8):894-7</RefSource><PMID Version="1">26508460</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2015 Sep 15;61(6):996-1003</RefSource><PMID Version="1">26060285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9</RefSource><PMID Version="1">21283017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2017 Feb;36(2):189-197</RefSource><PMID Version="1">27798548</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001724" MajorTopicYN="N">Birth Weight</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007230" MajorTopicYN="N">Infant, Low Birth Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018445" MajorTopicYN="N">Infectious Disease Transmission, Vertical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="Y">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28291053</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000001359</ArticleId><ArticleId IdType="pmc">PMC5553236</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000D75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28291053
|texte= Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28291053" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |